ECSP088511A - Agonistas del receptor del neuropeptido-2 - Google Patents
Agonistas del receptor del neuropeptido-2Info
- Publication number
- ECSP088511A ECSP088511A EC2008008511A ECSP088511A ECSP088511A EC SP088511 A ECSP088511 A EC SP088511A EC 2008008511 A EC2008008511 A EC 2008008511A EC SP088511 A ECSP088511 A EC SP088511A EC SP088511 A ECSP088511 A EC SP088511A
- Authority
- EC
- Ecuador
- Prior art keywords
- neuropeptido
- agonists
- receiver agonists
- receiver
- neuropeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Se proporcionan agonistas del receptor del neuropéptido-2 de fórmula (I): Y' | Y-R1-R2-X-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-NH2 (I),así como las sales farmacéuticamente aceptables, derivados y fragmentos del mismo, en el que los sustituyentes son tal y como se describen en la especificación. Estos compuestos, y las composiciones farmacéuticas que los contienen, son útiles para el tratamiento de enfermedades como, por ejemplo, la obesidad y la diabetes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74807105P | 2005-12-07 | 2005-12-07 | |
US85524906P | 2006-10-30 | 2006-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088511A true ECSP088511A (es) | 2008-07-30 |
Family
ID=37964711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008511A ECSP088511A (es) | 2005-12-07 | 2008-06-06 | Agonistas del receptor del neuropeptido-2 |
Country Status (18)
Country | Link |
---|---|
US (2) | US7642244B2 (es) |
EP (1) | EP1962959B1 (es) |
JP (1) | JP5000663B2 (es) |
KR (1) | KR101059602B1 (es) |
AR (1) | AR057222A1 (es) |
AT (1) | ATE549350T1 (es) |
AU (1) | AU2006324076A1 (es) |
BR (1) | BRPI0619573A2 (es) |
CA (1) | CA2630649A1 (es) |
EC (1) | ECSP088511A (es) |
ES (1) | ES2381497T3 (es) |
IL (1) | IL191636A (es) |
MA (1) | MA30142B1 (es) |
NO (1) | NO20082445L (es) |
NZ (1) | NZ568772A (es) |
RU (2) | RU2430108C2 (es) |
TW (1) | TWI321474B (es) |
WO (1) | WO2007065808A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010069242A (ko) * | 2000-09-05 | 2001-07-25 | 양우용 | 저주파 물리치료 겸용 혈압 강하기 |
NZ568772A (en) * | 2005-12-07 | 2010-05-28 | Hoffmann La Roche | Truncated analogs of the peptide pYY3-36 that are neuropeptide-2 receptor-agonists |
US8299023B2 (en) | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
CA2741921A1 (en) * | 2008-11-05 | 2010-05-14 | F. Hoffmann-La Roche Ag | Neuropeptide-2-receptor (y-2r) agonists and uses thereof |
US9260500B2 (en) | 2009-07-02 | 2016-02-16 | Takeda Pharmaceutical Company Limited | Peptide and use thereof |
CN102573888A (zh) * | 2009-09-18 | 2012-07-11 | 诺和诺德公司 | 长效y2 受体激动剂 |
EP2488195A2 (en) * | 2009-10-13 | 2012-08-22 | F. Hoffmann-La Roche AG | Neuropeptide-2 receptor (y-2r) agonists |
US9278123B2 (en) | 2010-12-16 | 2016-03-08 | Novo Nordisk A/S | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
BR112013014644A2 (pt) | 2011-01-03 | 2017-03-07 | F Hoffmann - La Roche Ag | composição farmacêutica e complexo |
RS64460B1 (sr) | 2012-03-22 | 2023-09-29 | Novo Nordisk As | Kompozicije glp-1 peptida i njihova priprema |
AU2013285422B2 (en) | 2012-07-04 | 2017-04-27 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
PL2869837T3 (pl) | 2012-07-04 | 2017-03-31 | F.Hoffmann-La Roche Ag | Przeciwciała przeciw teofilinie i sposoby ich stosowania |
JP6247287B2 (ja) | 2012-07-04 | 2017-12-13 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗ビオチン抗体および使用方法 |
RS59026B1 (sr) | 2013-11-15 | 2019-08-30 | Novo Nordisk As | Selektivna pyy jedinjenja i njihova upotreba |
JP6629198B2 (ja) | 2013-11-15 | 2020-01-15 | ノヴォ ノルディスク アー/エス | 35位にβ−ホモアルギニン置換を有するHPYY(1−36) |
WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
EP3089758B1 (en) | 2014-01-03 | 2021-01-27 | F.Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
BR112016014945A2 (pt) | 2014-01-03 | 2018-01-23 | F. Hoffmann-La Roche Ag | conjugado, formulação farmacêutica e uso |
MA41898A (fr) * | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
CA2988500A1 (en) | 2015-06-12 | 2016-12-15 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
PL3746111T3 (pl) | 2018-02-02 | 2024-01-15 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
AUPO029096A0 (en) | 1996-06-05 | 1996-07-04 | Crc For Biopharmaceutical Research Pty Ltd | Npy y2 agonists |
US6013633A (en) | 1997-08-07 | 2000-01-11 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
EP2277527A3 (en) * | 2003-01-17 | 2011-08-31 | Ipsen Pharma | Peptide YY analogs |
CA2843439A1 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Reversible pegylated drugs |
JP2007512365A (ja) | 2003-11-25 | 2007-05-17 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 選択的神経ペプチドy2受容体作動薬 |
WO2005080424A2 (en) | 2004-02-23 | 2005-09-01 | Rheoscience A/S | Peptide yy analogues |
US7410949B2 (en) * | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
WO2006091505A2 (en) | 2005-02-24 | 2006-08-31 | Bayer Pharmaceuticals Corporation | Neuropeptide y receptor agonists |
NZ568772A (en) * | 2005-12-07 | 2010-05-28 | Hoffmann La Roche | Truncated analogs of the peptide pYY3-36 that are neuropeptide-2 receptor-agonists |
WO2007085887A1 (en) | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Pyy agonists and uses thereof |
-
2006
- 2006-11-27 NZ NZ568772A patent/NZ568772A/en not_active IP Right Cessation
- 2006-11-27 EP EP06830133A patent/EP1962959B1/en active Active
- 2006-11-27 CA CA002630649A patent/CA2630649A1/en not_active Abandoned
- 2006-11-27 KR KR1020087016291A patent/KR101059602B1/ko not_active IP Right Cessation
- 2006-11-27 BR BRPI0619573-3A patent/BRPI0619573A2/pt not_active IP Right Cessation
- 2006-11-27 AU AU2006324076A patent/AU2006324076A1/en not_active Abandoned
- 2006-11-27 RU RU2008127265/04A patent/RU2430108C2/ru not_active IP Right Cessation
- 2006-11-27 ES ES06830133T patent/ES2381497T3/es active Active
- 2006-11-27 JP JP2008543768A patent/JP5000663B2/ja not_active Expired - Fee Related
- 2006-11-27 WO PCT/EP2006/068924 patent/WO2007065808A2/en active Application Filing
- 2006-11-27 AT AT06830133T patent/ATE549350T1/de active
- 2006-12-01 US US11/607,230 patent/US7642244B2/en not_active Expired - Fee Related
- 2006-12-04 TW TW095145032A patent/TWI321474B/zh not_active IP Right Cessation
- 2006-12-05 AR ARP060105368A patent/AR057222A1/es active IP Right Grant
-
2008
- 2008-05-22 IL IL191636A patent/IL191636A/en not_active IP Right Cessation
- 2008-05-28 NO NO20082445A patent/NO20082445L/no not_active Application Discontinuation
- 2008-06-06 EC EC2008008511A patent/ECSP088511A/es unknown
- 2008-07-01 MA MA31085A patent/MA30142B1/fr unknown
-
2009
- 2009-08-06 US US12/536,688 patent/US8268784B2/en not_active Expired - Fee Related
-
2011
- 2011-02-15 RU RU2011105310/04A patent/RU2011105310A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200806311A (en) | 2008-02-01 |
JP2009518349A (ja) | 2009-05-07 |
KR101059602B1 (ko) | 2011-08-25 |
NO20082445L (no) | 2008-09-03 |
EP1962959A2 (en) | 2008-09-03 |
CA2630649A1 (en) | 2007-06-14 |
ES2381497T3 (es) | 2012-05-28 |
RU2430108C2 (ru) | 2011-09-27 |
TWI321474B (en) | 2010-03-11 |
IL191636A0 (en) | 2008-12-29 |
RU2011105310A (ru) | 2012-08-20 |
EP1962959B1 (en) | 2012-03-14 |
US20070135351A1 (en) | 2007-06-14 |
MA30142B1 (fr) | 2009-01-02 |
US8268784B2 (en) | 2012-09-18 |
AR057222A1 (es) | 2007-11-21 |
NZ568772A (en) | 2010-05-28 |
RU2008127265A (ru) | 2010-01-20 |
US7642244B2 (en) | 2010-01-05 |
BRPI0619573A2 (pt) | 2011-10-04 |
KR20080082672A (ko) | 2008-09-11 |
US20100137223A1 (en) | 2010-06-03 |
ATE549350T1 (de) | 2012-03-15 |
JP5000663B2 (ja) | 2012-08-15 |
WO2007065808A3 (en) | 2007-08-02 |
WO2007065808A2 (en) | 2007-06-14 |
AU2006324076A1 (en) | 2007-06-14 |
IL191636A (en) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP088511A (es) | Agonistas del receptor del neuropeptido-2 | |
AR051904A1 (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r) | |
ECSP088120A (es) | Derivados de piridazinona como agonistas del receptorde la hormona tiroidea | |
ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
CL2008002793A1 (es) | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras | |
GT200600114A (es) | Derivados de ciclopropanocarboxamida | |
CL2008002768A1 (es) | Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades. | |
CR7743A (es) | Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf) | |
CR20110077A (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol | |
CR10621A (es) | Derivados de adenosina como agonistas del receptor a2a | |
UY30759A1 (es) | Compuestos quimicos | |
UY30267A1 (es) | Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones | |
TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
ECSP109934A (es) | Compuesto - 946 | |
PA8577101A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
DOP2006000061A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
CR8270A (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
TW200643013A (en) | Pyrazoles | |
MX2009000169A (es) | Derivados de purinona como agonistas de hm74a. | |
IN2012DN03042A (es) | ||
ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
WO2010052144A3 (en) | Neuropeptide-2-receptor (y-2r) agonists and uses thereof | |
CO6321280A2 (es) | Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas |